Navigation Links
Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
Date:3/11/2008

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the discovery and development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that an abstract detailing results from the RAV12 Phase 1/2a trial has been accepted as a poster discussion presentation at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). The presentation is scheduled for May 30, 2008. Dr. Nancy Lewis of the Fox Chase Cancer Center is the abstract's first author and will make the presentation on behalf of the study's participating investigators.

The study, which enrolled 53 patients with adenocarcinomas bearing the RAAG12 antigen, particularly those of gastrointestinal (GI) origin, was conducted at 5 institutions in the US, the Sarah Cannon Cancer Center in Nashville, TN; the Fox Chase Cancer Center in Philadelphia, PA; Premiere Oncology in Santa Monica, CA; the University of Miami Medical Center in Miami, FL; and the Georgetown University Medical Center in Washington, DC.

About GI Cancers

Adenocarcinomas are malignant tumors of the epithelial cells that line glands or viscera. They typically spread by way of the circulatory or lymphatic systems and are poorly treated after metastatic dissemination. More than 90 percent of colon, stomach and pancreatic tumor specimens express the RAV12-defined antigen, RAAG12. Adenocarcinomas arising elsewhere, such as breast, endometrial, ovarian, lung and prostate, display the antigen at lower frequency.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody that is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, and colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacious in human colon, gastric, and pancreatic tumor xenograft models in vivo and has been found to be well tolerated in repeat dose primate toxicology studies.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven's discovery process simultaneously identifies cell-surface drug targets and the antibody therapeutics to regulate them. Our focus on biological function allows us to rapidly identify novel target antigens and therapeutic candidates in their native configuration in the intact cell membrane. Our integrated approach is based on proprietary methods for optimizing the production of MAbs targeting cell-surface proteins, including the use of human tissue-specific progenitor and tumor stem cell lines developed at Raven.

To date Raven has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer.

On November 12, 2007, Raven and VaxGen Inc. (Pink Sheets: VXGN.PK), a biopharmaceutical company, announced that their respective boards of directors unanimously approved a definitive merger agreement. The merger is expected to create a drug development company with a robust pipeline of monoclonal antibody candidates in oncology, proprietary antibody discovery platforms, biopharmaceutical manufacturing capabilities and sufficient cash to fund operations at least through the end of 2009. The merger is expected to close in the first half of 2008.


'/>"/>
SOURCE Raven biotechnologies, inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
3. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
8. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
9. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
10. Mentice AB Announces Leadership Changes Within Its Worldwide Operations
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Kablooe Design, a leading provider of product ... official 25th anniversary of the business. “We have worked hard to build long-term relationships,” ... for the privilege and honor of serving their product design and development needs through ...
(Date:5/19/2016)... RIDGE, British Columbia , May 19, 2016 ... AdvanTec Global Innovations Inc. (AGI), based out of ... recently added Greenlane Biogas Ltd. to its existing ... 2-year contract manufacturing agreement. AFS along with its ... Technologies (ABT) is a vertically integrated industrial group ...
(Date:5/19/2016)... -- - I dati saranno presentati nel ... ° Congresso della Società Americana ... - Le conclusioni dello studio indicano un tasso di risposta ... il 90% presenta una d urata della risposta (Duration ... per cento dei pazienti ha riscontrato un beneficio clinico. ...
(Date:5/18/2016)... ... May 18, 2016 , ... STACS DNA Inc., the sample tracking ... and report sexual assault kit processing to help them save time and reduce errors. ... for kits to be processed and victims informed of results. Due to a previous ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):